MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Voyager Therapeutics Net Income 2011-2026 | VYGR
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Voyager Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 132 M | -46.4 M | -71.2 M | 36.7 M | -43.6 M | -88.3 M | -70.7 M | -40.2 M | -29.7 M | -16.3 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | -88.3 M | -23.7 M |
Quarterly Net Income Voyager Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -27.9 M | -33.4 M | -31 M | - | -9.04 M | -10.1 M | -11.3 M | - | -25.9 M | -22.2 M | 124 M | - | 17.6 M | -19.1 M | -21.3 M | - | -25.1 M | -30.1 M | -21.6 M | - | 85.6 M | -8.68 M | -24.3 M | -12.6 M | -15 M | 11.2 M | -27.2 M | -22.5 M | -20.3 M | -25.5 M | -19.9 M | -11.8 M | -23.3 M | -18.9 M | -16.6 M | -14.7 M | -9 M | -9.34 M | -7.19 M | -8.82 M | -3.92 M | -3.9 M | -14.6 M | -5.2 M | -4 M | -4.86 M | -3.21 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 124 M | -33.4 M | -9.17 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-143 M | $ 2.13 | -12.55 % | $ 219 M |  USA |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
BioCardia
BCDA
|
-11.6 M | $ 1.37 | 6.2 % | $ 29 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
-69.7 M | $ 2.4 | -2.83 % | $ 132 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-27.1 M | $ 2.8 | -1.06 % | $ 908 M |  Israel |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-59.6 M | $ 1.64 | -1.8 % | $ 4.16 M | USA |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
BeyondSpring
BYSI
|
-11.1 M | $ 1.44 | 6.3 % | $ 58.1 M | USA |
 |
Cabaletta Bio
CABA
|
-67.7 M | $ 3.34 | 0.6 % | $ 3.9 M | USA |
 |
AbCellera Biologics
ABCL
|
-146 M | $ 3.7 | 2.49 % | $ 1.11 B |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Codexis
CDXS
|
-65.3 M | $ 1.05 | 3.47 % | $ 77.1 M | USA |
 |
Cerus Corporation
CERS
|
-20.9 M | $ 2.6 | 1.56 % | $ 480 M | USA |
 |
Certara
CERT
|
-1.6 M | $ 7.17 | 1.27 % | $ 1.15 B | USA |
 |
Cullinan Management
CGEM
|
-167 M | $ 15.91 | 2.65 % | $ 931 M | USA |
 |
Compugen Ltd.
CGEN
|
-14.2 M | $ 2.28 | 25.97 % | $ 204 M | Israel |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
Coherus BioSciences
CHRS
|
-238 M | $ 1.66 | -0.9 % | $ 156 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
-14.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
-125 M | $ 3.88 | - | $ 116 M | France |
 |
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-62.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-58.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-14.9 M | $ 3.1 | -0.44 % | $ 1.18 M | USA |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Cocrystal Pharma
COCP
|
-17.5 M | $ 1.02 | -0.97 % | $ 10.4 M | USA |
 |
Aptose Biosciences
APTO
|
-25.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Collegium Pharmaceutical
COLL
|
17 M | $ 42.0 | 0.79 % | $ 1.33 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
99.7 M | $ 35.61 | -0.25 % | $ 3.7 B | USA |
 |
Athira Pharma
ATHA
|
-96.9 M | - | - | $ 269 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-30.4 M | - | 17.91 % | $ 11.1 M | USA |